$STVN

Dal Lago Marco sold $85K of STVN

Dal Lago Marco (Chief Financial Officer) sold 4,209 shares of Stevanato Group S.p.A. (STVN) at $20.09 on 2026-08-07.

Original reporting
SEC EDGAR · Dal Lago Marco
Published Aug 10, 2026, 8:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 10, 2026, 8:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$STVN
Neutral
medium confidence
Mentioned
$STVN
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STVNNeutralLow
01

Why it matters

The newest fact is the disclosed open-market sale by the CFO, including share count, price, and post-transaction holdings. It is primarily sentiment-related rather than a fundamental re-rating catalyst.

02

Market read

Traders may note the CFO sale for sentiment, but there is no accompanying operational or financial update in the filing text provided.

03

What to watch

The article does not state whether the sale was part of a broader pattern, whether options were exercised, or whether other insiders sold around the same time.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-10 after-hours; transaction dated 2026-08-07

Background

The article is a SEC Form 4 insider transaction disclosure for Stevanato Group S.p.A. (STVN).

Company-level read

Ticker impact

$STVNNeutralMedium confidence
Context

Stevanato Group CFO Dal Lago Marco filed a Form 4 selling 4,209 shares at $20.0900 on 2026-08-07.

Expected impact

Likely limited near-term impact; any reaction should be small and fade unless follow-on selling or other news emerges.

Evidence & confidence

The filing provides transaction size and price but no accompanying company-specific news, guidance, or legal/regulatory development.

Market effects

No clear sector read-through from a single CFO open-market sale.

None indicated.

None indicated.

Counterpoint

Insider sales can be tax- or diversification-driven and may not signal reduced confidence, especially without any other negative company developments.

Key entities

  • Stevanato Group S.p.A.

    Company whose insider transaction was disclosed via Form 4.

  • Dal Lago Marco

    Chief Financial Officer who sold shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$STVNMedAI 8/10

Stevanato Group S.p.A. Q2 2026 Earnings Call Summary

Stevanato Group reported Q2 2026 revenue up 8%, with Biopharmaceutical and Diagnostic Solutions rising 9% and Engineering slightly down. High-value solutions grew 16% to 45% of revenue. Full-year 2026 guidance was raised to EUR 1.260-1.280 billion, citing a EUR 15 million Balda divestiture headwind. Alina variable dose pen received European regulatory approvals for liraglutide therapies.

$STVNMed

Stevanato (STVN) Q2 2026 Earnings Call Transcript

Stevanato Group (STVN) reported Q2 2026 revenue of EUR 302 million, up 8% year over year. High-value solutions rose 16% to EUR 135.9 million and were 45% of revenue. Gross margin increased 60 bps to 28.7%. Stevanato completed the sale of its California subsidiary Balda C. Brewer, recording EUR 12.2 million one-time expenses.

$STVNMed

Stevanato Group S.p.A. (STVN): Financial results for Q2 2026

Stevanato Group S.p.A. (STVN) furnished an SEC Form 6-K — earnings release. EXHIBIT 99.1 Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026 - The Company Divests its California-Based Subsidiary, Balda C. Brewer, Inc - (PIOMBINO DESE, Italy) – August 4, 2026 – Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of

$STVNMedAI 8/10

Stevanato Group S.p.A.: Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026

Stevanato Group (NYSE: STVN) reported Q2 fiscal 2026 revenue up 8% to €302.0m, with high-value solutions up 16% to €135.9m (45% of sales). Adjusted EBITDA margin rose to 26.0%. The company completed the sale of its California subsidiary Balda C. Brewer, incurring €12.2m expenses, and updated FY2026 guidance to revenue €1.260-€1.280b and adjusted EBITDA €335.0-€345.2m.